Skip to main content
SpringerLink
Log in

A new look at dry eye disease and its treatment

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

This review examines the impact of moderate to severe dry eye disease on daily life and medical-resource utilization. The results suggest that current treatment paradigms can lead to unacceptable costs in both quality of life and progressive use of healthcare resources. Evidence linking this disease to T-cell-mediated inflammatory processes lays the foundation for understanding the clinical benefits of topical cyclosporine, an immunomodulatory and anti-inflammatory agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes.CLAOJ. 1995;21:221–232.

    CAS  Google Scholar 

  2. Lubniewski AJ, Nelson JD. Diagnosis and management of dry eye and ocular surface disorders.Ophthalmol Clin North Am. 1990;3:575–594.

    Google Scholar 

  3. Lemp MA. Recent developments in dry eye management.Ophthalmology. 1987;1299-1304.

  4. Mackie IA, Seal DV. Diagnostic implication of tear protein profiles.Br J Ophthalmol. 1984;68: 321–324.

    Article  PubMed  CAS  Google Scholar 

  5. Seal DV. The effect of aging and disease on tear constituents.Trans Ophthalmol Soc UK. 1985; 104:355–362.

    PubMed  Google Scholar 

  6. Lemp MA, Mahmood MA, Weiler HH. Association of rosacea and keratoconjunctivitis sicca.Arch Ophthalmol. 1984;102:556–557.

    PubMed  CAS  Google Scholar 

  7. Scott IU, Flynn HW, Feuer W, et al. Endophthalmitis associated with microbial keratitis.Ophthalmology. 1996;103:1864–1870.

    PubMed  CAS  Google Scholar 

  8. Hirsch JD, Kozma CM, Wojcik AR, Reis B. Economic and quality of life impact of dry eye symptoms: a Sjögren’s patient survey.Invest Ophthalmol Vis Sci. 1998;39:S65. Abstract.

    Google Scholar 

  9. Stevenson D, Tauber J, Reis B, the Cyclosporin A Phase 2 Study Group. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial.Ophthalmology, in press.

  10. Sall K, Stevenson OD, Mundorf TK, Reis B, the CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease.Ophthalmology. 2000;107:631–639.

    Article  PubMed  CAS  Google Scholar 

  11. Damato BE, Allan D, Murray SB, Lee WR. Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease.Br J Ophthalmol. 1984;68:674–680.

    Article  PubMed  CAS  Google Scholar 

  12. Pflugfelder SC, Wilhelmus KR, Osato AS, et al. The autoimmune nature of aqueous tear deficiency.J Ophthalmol. 1986;93:1513–1517.

    CAS  Google Scholar 

  13. Williamson J, Gibson AAM, Wilson T, Forrester JV, Whaley K, Kick WC. Histology of the lacrimal gland in keratoconjunctivitis sicca.Br J Ophthalmol. 1973;57:852–858.

    Article  PubMed  CAS  Google Scholar 

  14. Stern ME, Beuerman R, Fox RL, Gao J, Mircheff AK, Pflugfelder S. The pathophysiology of dry eye: the interaction between the ocular surface and lacrimal glands.Cornea. 1998;17:584–589.

    Article  PubMed  CAS  Google Scholar 

  15. Kroemer G, Martinez A. Cytokines and autoimmune disease.Clin Immunol Immunopathol. 1991;61:275–295.

    Article  PubMed  CAS  Google Scholar 

  16. Smith JA, Stern ME, Gao J, Schwalb TA, Whitcup SM. Evaluation of the conjunctival cell cycle environment in keratoconjunctivitis sicca (KCS).Invest Ophthalmol Vis Sci. 1999;40:S559. Abstract.

    Google Scholar 

  17. Pepose JS, Akata RF, Pflugfelder SC, Vorgt W. Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjögren’s syndrome.Ophthalmology. 1990;97:1599–1605.

    PubMed  CAS  Google Scholar 

  18. Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis B. Interleukin-6 levels in the conjunctival epithelium of patients with keratoconjunctivitis sicca treated with cyclosporine ophthalmic emulsion.Invest Ophthalmol Vis Sci. 1999;40:S558. Abstract.

    Google Scholar 

  19. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Effect of cyclosporine ophthalmic emulsion on the number of inflammatory cells and goblet cells in conjunctival biopsies of patients with dry eye.Invest Ophthalmol Vis Sci. 1999;40:S771. Abstract.

    Google Scholar 

  20. Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease.Arch Ophthalmol. 1984;102:1049–1051.

    PubMed  CAS  Google Scholar 

  21. Kaswan RL, Salisbury M-A, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops.Arch Ophthalmol. 1989;1210-1216.

  22. Morgan RV, Abrams KL. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs.J Am Vet Med Assoc. 1991;199:1043–1046.

    PubMed  CAS  Google Scholar 

  23. Olivero DK, Davidson MG, English RV, Nasisse MP, Jamieson VE, Gerig TM. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs.J Am Vet Med Assoc. 1991;199:1039–1042.

    PubMed  CAS  Google Scholar 

  24. Webster DL. A comparative approach to topical cyclosporine therapy.Eye. 1997;11:453–464.

    Google Scholar 

  25. Foulks GN, Pflugfelder SC, Lemp MA, Stern KL, Burk CT, Reis BL. A randomized doublemasked clinical trial to assess efficacy and safety of a 1% CsA-containing ophthalmic ointment vs placebo in patients with keratoconjunctivitis sicca (KCS) associated with Sjögren’s syndrome (SS).Invest Ophthalmol Vis Sci. 1996;37:S646. Abstract.

    Google Scholar 

  26. Helms HA, Rapoza P, Stern KL, Burk CT, Rosenthal A, Reis BL. A randomized double-masked clinical trial to assess the safety and comparative efficacy of three concentrations of a cyclosporinecontaining ophthalmic ointment vs placebo in patients with keratoconjunctivitis sicca (KCS).Invest Ophthalmol Vis Sci. 1996;37:S646. Abstract.

    Google Scholar 

  27. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca.Cornea. 1993;124:311–323.

    Google Scholar 

  28. Power WJ, Mullaney P, Farrell M, Collum LM. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjögren’s syndrome.Cornea. 1993;12:507–511.

    Article  PubMed  CAS  Google Scholar 

  29. Calne RY, White PJG. The use of cyclosporin A in clinical organ grafting.Ann Surg. 1982;9:330–335.

    Article  Google Scholar 

  30. Kirby B, Harrison PV. Combination low-dose cyclosporin (Neoral) and hydroxyurea for severe recalcitrant psoriasis.Br J Dermatol. 1999;140:186–187.

    Article  PubMed  CAS  Google Scholar 

  31. Popovic M, Stefanovic D, Pejnovic N, et al. Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporine, and levamisole) in patients with rheumatoid arthritis.Transplant Proc. 1998;30:4135–4136.

    Article  PubMed  CAS  Google Scholar 

  32. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease.Cornea. 1993;12:413–419.

    Article  PubMed  CAS  Google Scholar 

  33. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A. Background, immunology, and pharmacology.Cornea. 1990;9:184–195.

    Article  PubMed  CAS  Google Scholar 

  34. Gundoz K, Özdemir Ö. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome.Acta Ophthalmol. 1994;72:438–442.

    Article  Google Scholar 

  35. Schiffman RM, Muhich A, Christianson M, et al. The reliability and validity of the Ocular Surface Disability Index (OSDI).Invest Ophthalmol Vis Sci. 1998;39:S65. Abstract.

    Google Scholar 

  36. Evens C, Crawford B. Patient self-reports in pharmacoeconomic studies: their use and impact on study validity.Pharmacoeconomics. 1999;15:241–256.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HealthPartners Medical Group, Minneapolis Regions Hospital, St. Paul

    J. Daniel Nelson M.D.

  2. The University of Minnesota, Minneapolis, Minnesota

    J. Daniel Nelson M.D.

  3. Birmingham, Alabama

    Harold Helms M.D.

  4. University of Illinois, Chicago, Illinois

    Richard Fiscella R.Ph., M.P.H.

  5. Caremark Northbrook, Illinois

    Yvonne Southwell R.Ph.

  6. Allergan, Inc., Irvine, California

    Jan D. Hirsch Ph.D.

Authors
  1. J. Daniel Nelson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harold Helms M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Fiscella R.Ph., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yvonne Southwell R.Ph.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jan D. Hirsch Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nelson, J.D., Helms, H., Fiscella, R. et al. A new look at dry eye disease and its treatment. Adv Therapy 17, 84–93 (2000). https://doi.org/10.1007/BF02854841

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02854841

Keywords

Search

Navigation